Savings & Resources | Lexette® Foam (halobetasol propionate)

Patients can save on their LEXETTE Foam prescription at participating retail and specialty pharmacies nationwide*

download Patient Savings card

Download the card, no activation required
Remind patients to take their LEXETTE Foam prescription and Mayne Pharma Patient Savings Card to the pharmacy

Here’s what your patients can expect to pay*

$0

for most insured, eligible, covered patients

and

As little as $65

for most uncovered, eligible patients

Out-of-pocket costs may vary.

*Complete Terms, Conditions, and Eligibility Criteria are included with the Mayne Pharma Patient Savings Card.

Lexette Foam is available to patients in 50 grams or 100 grams (two 50-gram cans)

LEXETTE Foam patient brochure

Savings is just one of the things we offer to help your patients. This brochure has savings information and instructions for how to apply LEXETTE Foam.

Download brochure

Request a visit from a rep

Connect with a Mayne Pharma Sales Specialist to get more information about LEXETTE Foam and to request samples.

Request now

Take a look at another foam for plaque psoriasis from Mayne Pharma >

Indication

LEXETTE^® Foam (halobetasol propionate) is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years and older.

Important Safety Information

LEXETTE^® Foam (halobetasol propionate) is a topical corticosteroid that has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Systemic effects of topical corticosteroids may include reversible HPA axis suppression, with the potential for glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of treatment of the topical corticosteroid.

The potential for hypothalamic-pituitary adrenal (HPA) suppression with LEXETTE Foam was evaluated in a study of 25 adult subjects with moderate to severe plaque psoriasis involving ≥15% of their body surface area. LEXETTE Foam produced laboratory evidence of HPA axis suppression when used twice daily for two weeks in 6 out of 25 (24%) adult subjects with plaque psoriasis. Recovery of HPA axis function was generally prompt with the discontinuation of treatment.

Systemic effects of topical corticosteroids may also include Cushing's syndrome, hyperglycemia, and glucosuria. Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids.

Local adverse reactions from topical corticosteroids may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. These may be more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids, including LEXETTE Foam.

Some local adverse reactions may be irreversible. Use of topical corticosteroids may increase the risk of posterior subcapsular cataracts and glaucoma.

To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Excellent access and affordability with the mayne pharma patient savings card